Navigation Links
The Association for Molecular Pathology celebrates ruling in DNA patent case
Date:4/1/2010

Washington, DC March 31, 2010 The Association for Molecular Pathology (AMP) is an international medical and professional association representing approximately 1,800 physicians, doctoral scientists, and medical laboratory scientists who perform laboratory testing based on knowledge derived from molecular biology, genetics, and genomics. AMP applauds US District Judge Robert Sweet's ruling in favor of the plaintiffs in the lawsuit, Association for Molecular Pathology, et al. v. U.S. Patent and Trademark Office, et al. "This is a landmark decision that has the potential to dramatically improve patient access to genetic testing. It is a boon to personalized medicine in the purest sense as nothing is more personal than one's genetic makeup. This judgment removes numerous barriers and impediments to clinical research, testing, and innovation since patented genes cannot be invented around, and has implications for how we evaluate each and every patient's genetic information" said Dr. Karen Mann, AMP President.

In 2008, AMP adopted a Policy Statement (http://www.amp.org/Gov/Positions.htm) on gene patenting and the licensing of intellectual property that urged an end to the practice of granting patents on single genes, sequences of the genome or correlations between genetic variations and biological states. AMP also encouraged groups that currently hold gene patents, including higher educational and research institutions, not to grant exclusive licenses to access those patents.

The case was originally filed on May 12, 2009 in U.S. District Court for the Southern District of New York against the U.S. Patent and Trademark Office (PTO) and Myriad Genetics and the University of Utah Research Foundation, which hold the patents on the BRCA genes. The plaintiffs include organizations representing over 150,000 researchers and pathologists, breast cancer and women's health groups, and individual women.

"DNA patents have delayed, limited, or even shut down clinical testing and scientific research," added Dr. Mann, "and in the case of the BRCA genes, Myriad's lab is the only place in the country that performs full sequencing of the genes for diagnostic purposes. Patients can't get a second opinion before they make major, irreversible health decisions."

The summary judgment released yesterday is a significant step forward to eliminating future DNA patents and calls into question the appropriateness of those already in existence. This ruling will most definitely advance the development of personalized, molecular medicine and the practice of molecular pathology.


'/>"/>

Contact: Mary Steele Williams
mwilliams@amp.org
301-634-7921
Association for Molecular Pathology
Source:Eurekalert

Related medicine news :

1. Health Care Reform Law Could Improve Children's Oral Health, states Delta Dental Plans Association
2. Feeding America's David Arquette and Courteney Cox Team Up With the National Association of Letter Carriers to Stamp Out Hunger™
3. National Debt Relief Group Celebrates Proud Membership with TASC (The Association for Settlement Companies)
4. Grand Canyon University Nursing School Announces Three-Year Partnership with American Heart Association
5. The American Heart Association's The Heart of Diabetes Campaign is Helping Patients 'Know Your Diabetes' Better
6. National Medical Association, Health System Reform - From Legislation to Implementation
7. National Restaurant Association Says Nutrition Information Provision Is Win for Consumers and Restaurants
8. National Hispanic Medical Association Urges U.S. to Improve Health Care Access as Doctors Meet March 25-28 in Washington
9. Catholic Health Association Congratulates Nations Leaders For Enacting Historic Health Reform
10. VIDEO from Medialink and National Fibromyalgia Association and Pfizer Inc.: The Science Behind Fibromyalgia
11. Statement From Larry Minnix, President & CEO, American Association of Homes and Services for the Aging, on the Beginning of the Reconciliation Process for Health Reform Legislation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... DC (PRWEB) , ... April ... ... Association (ATA) is thrilled to announce the ATA 2017 President’s Awards recipients, ... innovation and demonstrated superior healthcare delivery. , The ATA 2017 President’s ...
(Date:4/26/2017)... ... , ... Infertility may be a result of an underlying ... women become pregnant upon treating their diagnosis. , To properly diagnose ... We can provide the necessary information to diagnose and treat your problem. ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... ecosystem and domain expertise for sponsors and CROs to speed clinical development, ... management (RTSM) software platform. Bioclinica AGILE RTSM provides seamless clinical ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, ... cells) Phase I/II HOPE clinical trial in Duchenne announced today. , Coalition ...
(Date:4/25/2017)... ... ... Lake Park Dental is now accepting new patients with crooked teeth who ... the help of this highly-effective, yet convenient system, patients can straighten their teeth and ... pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear and Elizabeth Dy, of ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/19/2017)... N.J. , April 19, 2017  Novartis ... by the National Heart, Lung, and Blood Institute ... demonstrating that 58% of patients with treatment-naïve severe ... months when treated with eltrombopag at the initiation ... . The study evaluated three sequential treatment groups, ...
Breaking Medicine Technology: